Despite two failed late-stage trials, Palo Alto-based biotech Kodiak Sciences said it’s going to restart development of its potential Eylea rival after it met all its endpoints in a trial for diabetic retinopathy, which can cause blindness in diabetic patients.
Kodiak originally paused the development program…
Click here to view original post
